← All trials
NCT05563272
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2022
- Primary completion
- Oct 8, 2025
- Completion date
- Dec 29, 2025
- First posted
- Oct 3, 2022
- Last posted
- Oct 3, 2022
- Enrollment
- 100
- Arms / groups
- — / —
- Source
- AACT · ctgov ingestion
Sponsors
- TelixLead sponsor
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Carcinoma, Ovarian Epithelial
- Nasopharyngeal Carcinoma
- Urinary Bladder Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Transitional Cell
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Glioblastoma
- Carcinoma, Hepatocellular
- von Hippel-Lindau Disease
- Mesothelioma
- Pancreatic Neoplasms
- Sarcoma
- Stomach Neoplasms
- Colorectal Neoplasms
- Cholangiocarcinoma
- Small Cell Lung Carcinoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.